In 2022, the global Quadriplegia Treatment Market is anticipated to be worth $1,468.4 million USD. The market's expansion might be attributed mostly to an increase in the frequency of spinal cord injuries, as well as an increase in the number of car accidents that occur globally each year. Between 2022 and 2032, the global demand for quadriplegia therapy is expected to expand at a CAGR of 4.7%, totalling roughly US$ 2,324.4 Million by 2032.
Key Drivers of Quadriplegia Treatment Market
Quadriplegia is caused by injury to the spinal cord caused by trauma to the base of the neck or the skull. Accidental paralysis, spinal cord tumours, and other spinal cord disorders are some of the most common causes of quadriplegia, also known as tetraplegia. A spinal cord injury can cause limb paralysis, either partial or full. According to the Spinal Cord Injury Statistics 2020 data sheet, approximately 17,810 new cases of spinal cord injuries are expected in the United States per year. Some of the reasons of quadriplegia include stroke, vehicle accidents, falls, violence, sports, medical or surgical causes, and others.
According to WHO estimates, 20-50 million people are injured in road traffic accidents each year, resulting in non-fatal injuries but long-term impairment. The need for quadriplegia therapy is likely to increase over the forecast period due to an increase in traffic accidents. Recent technological improvements and various R&D projects in the field of quadriplegia therapy are two of the key drivers driving demand in the next years. Patients with spinal cord injuries are becoming more aware of the various therapy options available to improve their quality of life.
Key player of Quadriplegia Treatment Market
Major manufacturers of medications needed to treat quadriplegia are
- Merck & Co.
- Sanofi Pharmaceuticals
- Baxter International
- Zydus Cadila
- GlaxoSmithKline
- AstraZeneca
- Cipla
- Johnson & Johnson
- Bristol Myers Squibb Co.
- Eli Lily & Co.
- Teva Pharmaceuticals
- Takeda Pharmaceutical Co Ltd
- Hoffmann La Roche
- Sun Pharmaceuticals.
Read More@ https://www.futuremarketinsights.com/reports/quadriplegia-treatment-market
Key Segments
By Treatment Type:
- Corticosteroids
- Non- Steroidal Anti-inflammatory Drugs (NSAIDs)
- Antidepressants
- Selective serotonin reuptake inhibitors (SSRIs)
- Serotonin and norepinephrine reuptake inhibitors (SNRIs)
- Anticonvulsants
- Narcotic Analgesics
- Antispasmodics & Muscle Relaxants
- Antibiotics
By Route of Administration:
- Oral
- Intravenous
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Stores
The new report by Expert Market Research titled, ‘Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment Market Report and Forecast 2021-2026’, gives an in-depth analysis of the global ABSSSI market, assessing the market based on its segments like infection type, route of administration, distribution channel, and major regions like Asia Pacific, Europe, North America, Middle East and Africa and Latin America.
The sample report shall be delivered to you within 24 hours.Request a free sample copy in PDF or view the report summary@https://www.expertmarketresearch.com/reports/acute-bacterial-skin-and-skin-structure-infections-absssi-treatment-market/requestsampleThe key highlights of the report include:Market Overview (2021-2026)Historical Market Size (2020): USD 9.3 BillionForecast CAGR (2021-2026): 7%Forecast Market Size (2026): USD 14 BillionThe growth of global ABSSSI is driven by the rising prevalence of skin infections.
Additionally, the developing antibiotic resistance in pathogenic bacteria, and mutations resulting in the newer strains is expected to drive the demand for the ABSSI Market.
Further the government spending on healthcare and infrastructure will propel the market in the forecast period.Industry Definition and Major SegmentsABSSSI are mild or severe forms infections caused by pathogens like streptococcus pyogenes and Staphylococcus aureus.
These drugs are pathogen specific and may require surgical excision of lesion in extreme cases.Explore the full report with the table of contents@https://www.expertmarketresearch.com/reports/acute-bacterial-skin-and-skin-structure-infections-absssi-treatment-marketThe acute bacterial skin and skin structure infections (ABSSSI) treatment industry can be segmented by infection type:Hospital-acquired ABSSSICommunity-acquired ABSSSIOthersIt may be differentiated on the basis of route of administration:OralParenteralThe industry may be classified on the basis of distribution channel:Hospital PharmacyRetail PharmacyOnlineOthersLatest Global News on Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment Market@https://www.expertmarketresearch.com/pressrelease/global-absssi-treatment-marketOn the basis of regional markets, the industry is divided into:1 North America1.1 United States of America1.2 Canada2 Europe2.1 Germany2.2 United Kingdom2.3 France2.4 Italy2.5 Others3 Asia Pacific3.1 China3.2 Japan3.3 India3.4 ASEAN3.5 Others4 Latin America4.1 Brazil4.2 Argentina4.3 Mexico4.4 Others5 Middle East & Africa5.1 Saudi Arabia5.2 United Arab Emirates5.3 Nigeria5.4 South Africa5.5 OthersMarket TrendsRegionally, North America is the largest shareholder in the global ABSSSI market, due to the presence of a robust healthcare system.
This can be attributed to the rapidly advancing healthcare sector, increasing population, and growing awareness about various skin aliments.Key Market PlayersThe major players in the market are Debiopharm International SA, Melinta Therapeutics, Inc., Paratek Pharmaceuticals, Inc., GlaxoSmithKline plc, and a few others.
